COVID-19 Drug Molnupiravir May Reduce Risk of Hospitalisation and Death in Newly-Diagnosed Patients, Says Health Expert Dr Krishna Reddy Nallamalla

Hyderabad, October 22: Anti-viral drug Molnupiravir might emerge as the sport changer in the battle in opposition to Covid-19 as research counsel it could possibly cut back the chance of hospitalisation or dying in newly-diagnosed sufferers, an knowledgeable says.

- Advertisement-

Distinguished heart specialist and well being programs knowledgeable Dr Krishna Reddy Nallamalla believes that Molnupiravir as an efficient oral drug for therapy of Covid-19 assumes significance as instances are nonetheless being reported regardless of vaccines, which aren’t as efficient in opposition to the unfold of the virus and have decrease efficacy in opposition to sure variants.

Almost two years because the onset of the pandemic, the world has reported near 250 million optimistic instances and 5 million deaths, whereas half 1,000,000 instances are nonetheless being reported daily.

- Advertisement-

“We have face masks, vaccines, and steroids to fight the pandemic. We also have the expensive injectable antiviral drug Remedesivir and the monoclonal antibody cocktail for those who can afford these. Most of the oral drugs, including chloroquine, ivermectin, anti-HIV drugs, anti-hepatitis drugs.. did not stand the scrutiny of scientific studies. Some others had weak evidence to be of large-scale,” stated Dr Krishna Reddy, who can be President of InOrder, a nonprofit institute working to strengthen programs to safe well being and Regional Director (South Asia) of international well being non-profit, ACCESS Health International. Molnupiravir, COVID-19 Antiviral Pill Cuts Risk of Hospitalisation, Deaths by 50% in Patients, Says Manufacturer.

“Despite the development of Covid-19 vaccines in a record time period, the world continues to witness daily positive cases of half a million. While vaccines have been effective against moderate to severe illness, they have not been as effective against the spread of the virus. In addition, the efficacy is lower against certain new variants. Another growing concern has been the rapid decline in neutralising antibodies within six months after the second dose necessitating the booster dose in people at high risk,” he stated.

He additionally identified that the inequity in entry to vaccines has been obvious inside and between international locations. On how Molnupiravir helps, Krishna Reddy stated that the fundamental constructing blocks of coronavirus are ribonucleic acids (RNA), and their analogues can produce mutations which can be deadly to the virus. While Remedesivir is an analogue and is demonstrated to cut back hospital keep in moderately-ill Covid sufferers, it’s costly and needs to be given by way of the intravenous route.

- Advertisement-

“Molnupiravir was earlier developed as an oral drug against influenza. It is also an analogue of ribonucleic acids, similar to Remedesivir. In a preprint published in June, virus isolation was noted in 1.6 per cent of those patients receiving Molnupiravir compared to 16.7 per cent of those receiving a placebo on day 3 and 0 per cent and 11.1 per cent respectively on day 5,” Krishna Reddy stated.

Merck and Ridgeback have introduced on October 11, the submission of an emergency use authorisation utility to the US FDA for the therapy of delicate to average instances (room air oxygen saturation greater than 93 per cent at relaxation).

- Advertisement-

The submission is predicated on optimistic outcomes from a deliberate interim evaluation from the section 3 MOVe-OUT scientific trial, which evaluated Molnupiravir in non-hospitalised adults with delicate to average Covid sickness who have been in danger to progress to extreme Covid requiring hospitalisation.

In the interim evaluation, there was a 50 per cent discount in danger of hospitalisation or dying (7.3 per cent with drug vs 14.1 per cent with placebo) with Molnupiravir. Full outcomes of the trial are awaited.

Merck has beforehand introduced that it has entered into non-exclusive voluntary licensing agreements for Molnupiravir with six established Indian generic producers to speed up the provision of the drug in greater than 100 low- and middle-income international locations (LMIC), following approval or EUA by their respective regulatory our bodies.

The arrival of an efficient and reasonably priced oral drug has lengthy been awaited in the battle in opposition to Covid-19 the world over and more so in LMIC that are but to obtain ample portions of vaccines.

There can be rising concern concerning the period of efficacy of the vaccines and their efficacy in opposition to new variants. Many wealthy international locations have began booster doses whereas many creating international locations are nonetheless ready for his or her first doses. COVID-19 Oral Drug: Hetero Announces Interim Clinical Trial Results of Antiviral Drug Molnupiravir in Mild Coronavirus Patients.

- Advertisement-

Krishna Reddy believes that India is in a novel place to provide the wanted vaccines to international locations awaiting them and additionally the reasonably priced generic oral Molnupiravir, to derive important geopolitical mileage.

“Reaching the milestone of one billion vaccine doses, India has exhibited remarkable resilience despite the devastating second wave that was driven by the Delta variant. It has restarted its vaccine exports to other countries. It is in a position to start exports of the new effective oral drug that the world has been eagerly awaiting,” he added.

(The above story first appeared on SociallyKeeda on Oct 22, 2021 05:49 PM IST. For more information and updates on politics, world, sports activities, entertainment and life-style, go online to our web site

Download Now

Stay Tuned with for more Entertainment information.

Socially Keeda

Socially Keeda, the pioneer of news sources in India operates under the philosophy of keeping its readers informed. tells the story of India and it offers fresh, compelling content that’s useful and informative for its readers.
Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker